FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Monday

 

Satisfaction with MS Therapy Influenced by Doctor-Patient Communication, Study Finds


























A study published in the BMC Neurology journal emphasized that clear and regular communication between physicians and patients with multiple sclerosis (MS) is essential for patient satisfaction with a given treatment, which could result in therapy persistence.

Uwe Zettl and colleagues conducted the study, “Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy,” comparing patient and physician satisfaction regarding the efficacy of interferon beta-1b — Betaferon — treatment. The report results from a prospective national cohort study, BETAPATH, conducted in Germany between 2009 and 2013.

MS is a chronic inflammatory disease of the central nervous system that requires long-term treatment. Disease modifying therapies (DMTs), such as Betaferon, are used in the clinic as a preventive treatment that can reduce the number of relapses and damage that MS can cause.

Interferon beta-1b therapy is commonly used and well-tolerated by patients. But the therapeutic success of the drug depends highly on patients’ adherence to treatment regimens and on long-term continuation. This is strongly influenced by healthcare professionals and physician involvement.

The study showed that both patients who continued with the treatment for two years, and their physicians, expressed high degrees of satisfaction with Betaferon therapy. The team also reported that patients and physicians who reported being unsatisfied with the therapy ultimately decided to discontinue its use. Therapeutic side effects and psychological symptoms, such as depression, may contribute to non-adherence, ultimately, termination.

Results indicated that it is important for patients and physicians to communicate clearly each one’s evaluation of the treatment, and their satisfaction levels, during scheduled appointments. Other healthcare professionals also have an important role in a patient’s satisfaction with Betaferon treatment, due to the fact that physicians often cannot invest the required time to appointments, so that MS nurses and medical assistants provide key services to patients.

The team also reported that the involvement of family members is important to patients’ satisfaction. Indeed, including family members into treatment plans can lead to better adherence to treatment.

Researchers concluded that better communication between patients and physicians, and coordination of continuity in medical care, are essential to maintaining and improving long-term DMT treatment in MS. Multidisciplinary approaches in therapy and psychological support are important factors in patients’ opinion of a treatment’s benefits, and on commitment to a DMT therapy.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News